Biotech Values

[corpstrat]

OT Yamanouchi. I guess Yamanouchi marketed Infergen outside US and never did take over the US rights, though there were negotiations for that. Looking back again at Amgen's commercial duds is quite sobering. Kepivance, Kineret and Stemgen as well as Infergen. That omits BDNF, GDNF, MGDF, Leptin, Abarelix and several that I don't recall that went far in the clinic. It's what makes me less sure than you that big companies make better P3 and launch decisions than small ones. The pressure for an encore to the blockbusters is intense.